GigaMune is a biotech firm focused on engineered TCR-Treg cell therapies for autoimmune diseases, including Type 1 Diabetes.
GigaMune's investors include Sequoia Capital, Heroic Ventures, Boost VC, National Cancer Institute, Bioverge.
GigaMune is headquartered in San Francisco, United States.
GigaMune is a biotech firm focused on engineered TCR-Treg cell therapies for autoimmune diseases, including Type 1 Diabetes.
GigaMune is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GigaMune — Funding & Investors." VCBacked, March 10, 2023, https://www.vcbacked.co/company/gigamune. Accessed September 5, 2026.
VCBacked. (2023). GigaMune — Funding & Investors. Retrieved September 5, 2026, from https://www.vcbacked.co/company/gigamune
{{cite web |title=GigaMune — Funding & Investors |url=https://www.vcbacked.co/company/gigamune |website=VCBacked |access-date=September 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated